Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase
Open Access
- 4 January 2021
- Vol. 9 (1), 19
- https://doi.org/10.3390/vaccines9010019
Abstract
Background: Evidence on whether the influenza vaccine could exacerbate immune-related adverse events, including myopericarditis (MP), in patients treated with immune checkpoint inhibitors (ICIs), is still conflicting. We explored this issue through a global real-world approach. Methods: We queried the Vaccine Adverse Event Reporting System (VAERS) and VigiBase to retrieve cases of MP in which the influenza vaccine and ICIs were recorded as suspect and were concomitantly reported. For the included cases, causality assessment and Drug Interaction Probability Scale (DIPS) algorithms were applied. Results: There were 191 and 399 reports of MP with the influenza vaccine that were retrieved (VAERS and VigiBase, respectively). No case of MP reporting the concomitant use of ICIs and the influenza vaccine was found in VAERS, while three cases of myocarditis were retrieved in VigiBase. All of the cases were unclassifiable for a causality assessment because of the lack of data concerning latency. According to the DIPS, one report was categorized as possible and two as doubtful. Conclusion: The paucity of cases coupled with the doubtful causality assessment make the potential interaction between influenza vaccines and ICIs in cancer patients negligible from clinical and epidemiological standpoints. These findings support the cardiovascular safety of the influenza vaccination, which remains strongly recommended in cancer patients, especially in the current COVID-19 era.This publication has 43 references indexed in Scilit:
- Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk PatientsJAMA, 2013
- Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesEuropean Heart Journal, 2013
- Drug-related cardiac pathologyJournal of Clinical Pathology, 2009
- Cardiovascular manifestations associated with influenza virus infectionInternational Journal of Cardiology, 2008
- Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasonsBMC Public Health, 2008
- Influenza Vaccination Coverage Rates in 5 European Countries: a Population-Based Cross-Sectional Analysis of the Seasons 02/03, 03/04 and 04/05Infection, 2007
- Proposal for a New Tool to Evaluate Drug Interaction CasesAnnals of Pharmacotherapy, 2007
- Epidemiology and outcomes of serious influenza‐related infections in the cancer populationCancer, 2005
- Adverse drug reactions: definitions, diagnosis, and managementThe Lancet, 2000
- An overview of the vaccine adverse event reporting system (VAERS) as a surveillance systemVaccine, 1999